<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829346</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-EC-OT-0-096/54</org_study_id>
    <nct_id>NCT02829346</nct_id>
  </id_info>
  <brief_title>Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty</brief_title>
  <official_title>Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the peri-articular tranexamic acid injection in total knee arthroplasty
      which is an alternative route of administration for blood loss reduction. Half of
      participants will receive intravenous tranexamic acid injection, while the other half will
      receive peri-articular tranexamic acid injection during total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous tranexamic acid (IV TXA) is one of the most effective agents in use for reducing
      blood loss following total knee arthroplasty (TKA) but its safety regarding venous
      thromboembolic events (VTEs) remains in question. The direct, local application of TXA may
      reduce systemic toxicity whilst maintaining good or better bleeding control compared to IV
      TXA. The topical application of TXA via Hemovac drains has been reported previously with good
      results. However, there are no data on peri-articular TXA injections during TKA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The volume of postoperative blood loss in the drain</measure>
    <time_frame>48 hours after the operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline hemoglobin concentrations</measure>
    <time_frame>48 hours after the operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>unit of blood transfusion</measure>
    <time_frame>48 hours after the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee diameter for swelling</measure>
    <time_frame>At 24 and 48 hours after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patient with venous thromboembolism</measure>
    <time_frame>At 14 days after the operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Peri-articular group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peri-articular tranexamic acid</intervention_name>
    <description>750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure</description>
    <arm_group_label>Peri-articular group</arm_group_label>
    <other_name>Transamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous tranexamic acid</intervention_name>
    <description>750 mg of IV TXA, prior to deflating the tourniquet and wound closure</description>
    <arm_group_label>Intravenous group</arm_group_label>
    <other_name>Transamin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with osteoarthritis in need of a TKA

        Exclusion Criteria:

          -  inflammatory arthritis

          -  post-traumatic arthritis

          -  a history of or current venous thromboembolic disease

          -  any underlying disease of haemostasis

          -  cirrhosis

          -  chronic renal failure

          -  patients on anticoagulants or strong antiplatelet drugs (e.g. warfarin, clopidogrel)

          -  know allergy to TXA

          -  defective color vision

          -  preoperative hemoglobin &lt;10 g/dL

          -  platelet count &lt; 140,000 /uL3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piya Pinsornsak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Thammasat university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopaedic department, Thammasat university hospital</name>
      <address>
        <city>Klongluang</city>
        <state>Pathumthani</state>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Sinclair KC, Clarke HD, Noble BN. Blood management in total knee arthroplasty: a comparison of techniques. Orthopedics. 2009 Jan;32(1):19.</citation>
    <PMID>19226044</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009 Feb;19(1):35-42. doi: 10.1111/j.1365-3148.2009.00908.x.</citation>
    <PMID>19302453</PMID>
  </reference>
  <reference>
    <citation>Parvizi J, Diaz-Ledezma C. Total knee replacement with the use of a tourniquet: more pros than cons. Bone Joint J. 2013 Nov;95-B(11 Suppl A):133-4. doi: 10.1302/0301-620X.95B11.32903.</citation>
    <PMID>24187371</PMID>
  </reference>
  <reference>
    <citation>Sabatini L, Trecci A, Imarisio D, Uslenghi MD, Bianco G, Scagnelli R. Fibrin tissue adhesive reduces postoperative blood loss in total knee arthroplasty. J Orthop Traumatol. 2012 Sep;13(3):145-51. doi: 10.1007/s10195-012-0198-7. Epub 2012 May 16.</citation>
    <PMID>22588333</PMID>
  </reference>
  <reference>
    <citation>Pitta M, Zawadsky M, Verstraete R, Rubinstein A. Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series. Transfusion. 2016 Feb;56(2):466-71. doi: 10.1111/trf.13354. Epub 2015 Oct 28.</citation>
    <PMID>26509250</PMID>
  </reference>
  <reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </reference>
  <reference>
    <citation>Aggarwal AK, Singh N, Sudesh P. Topical vs Intravenous Tranexamic Acid in Reducing Blood Loss After Bilateral Total Knee Arthroplasty: A Prospective Study. J Arthroplasty. 2015 Dec 21. pii: S0883-5403(15)01114-6. doi:10.1016/j.arth.2015.12.033. [Epub ahead of print]</citation>
  </reference>
  <reference>
    <citation>Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res. 1997 Feb 1;85(3):195-206. Erratum in: hromb Res 1997 Oct 15;88(2):251.</citation>
    <PMID>9058494</PMID>
  </reference>
  <reference>
    <citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. Review.</citation>
    <PMID>10400410</PMID>
  </reference>
  <reference>
    <citation>Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 Mar;18(3):132-8. Review.</citation>
    <PMID>20190103</PMID>
  </reference>
  <reference>
    <citation>Kluft C, Verheijen JH, Jie AF, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest. 1985 Nov;45(7):605-10.</citation>
    <PMID>3934744</PMID>
  </reference>
  <reference>
    <citation>Murphy WG, Davies MJ, Eduardo A. The haemostatic response to surgery and trauma. Br J Anaesth. 1993 Feb;70(2):205-13. Review.</citation>
    <PMID>7679584</PMID>
  </reference>
  <reference>
    <citation>Charoencholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011 Oct;469(10):2874-80. doi: 10.1007/s11999-011-1874-2. Epub 2011 Apr 22.</citation>
    <PMID>21512813</PMID>
  </reference>
  <reference>
    <citation>Orpen NM, Little C, Walker G, Crawfurd EJ. Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. Knee. 2006 Mar;13(2):106-10. Epub 2006 Feb 17.</citation>
    <PMID>16487712</PMID>
  </reference>
  <reference>
    <citation>Ortega-Andreu M, Pérez-Chrzanowska H, Figueredo R, Gómez-Barrena E. Blood loss control with two doses of tranexamic Acid in a multimodal protocol for total knee arthroplasty. Open Orthop J. 2011 Mar 16;5:44-8. doi: 10.2174/1874325001105010044.</citation>
    <PMID>21552468</PMID>
  </reference>
  <reference>
    <citation>Mannucci PM. Hemostatic drugs. N Engl J Med. 1998 Jul 23;339(4):245-53. Review.</citation>
    <PMID>9673304</PMID>
  </reference>
  <reference>
    <citation>Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007 May 31;356(22):2301-11. Review.</citation>
    <PMID>17538089</PMID>
  </reference>
  <reference>
    <citation>Ishida K, Tsumura N, Kitagawa A, Hamamura S, Fukuda K, Dogaki Y, Kubo S, Matsumoto T, Matsushita T, Chin T, Iguchi T, Kurosaka M, Kuroda R. Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop. 2011 Nov;35(11):1639-45. doi: 10.1007/s00264-010-1205-3. Epub 2011 Jan 21.</citation>
    <PMID>21253725</PMID>
  </reference>
  <reference>
    <citation>Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012 Sep;470(9):2605-12. doi: 10.1007/s11999-012-2310-y. Epub 2012 Mar 15.</citation>
    <PMID>22419350</PMID>
  </reference>
  <reference>
    <citation>Roy SP, Tanki UF, Dutta A, Jain SK, Nagi ON. Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012 Dec;20(12):2494-501. doi: 10.1007/s00167-012-1942-5. Epub 2012 Mar 15.</citation>
    <PMID>22419263</PMID>
  </reference>
  <reference>
    <citation>Wang H, Shen B, Zeng Y. Blood Loss and Transfusion After Topical Tranexamic Acid Administration in Primary Total Knee Arthroplasty. Orthopedics. 2015 Nov;38(11):e1007-16. doi: 10.3928/01477447-20151020-10. Review.</citation>
    <PMID>26558665</PMID>
  </reference>
  <reference>
    <citation>Spreng UJ, Dahl V, Hjall A, Fagerland MW, Ræder J. High-volume local infiltration analgesia combined with intravenous or local ketorolac+morphine compared with epidural analgesia after total knee arthroplasty. Br J Anaesth. 2010 Nov;105(5):675-82. doi: 10.1093/bja/aeq232. Epub 2010 Aug 24.</citation>
    <PMID>20736233</PMID>
  </reference>
  <reference>
    <citation>Manor D, Sadeh M. Muscle fibre necrosis induced by intramuscular injection of drugs. Br J Exp Pathol. 1989 Aug;70(4):457-62.</citation>
    <PMID>2765397</PMID>
  </reference>
  <reference>
    <citation>Pinsornsak P, Chumchuen S. Can a modified Robert Jones bandage after knee arthroplasty reduce blood loss? A prospective randomized controlled trial. Clin Orthop Relat Res. 2013 May;471(5):1677-81. doi: 10.1007/s11999-013-2786-0. Epub 2013 Jan 11.</citation>
    <PMID>23307631</PMID>
  </reference>
  <reference>
    <citation>Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009 Mar;123(5):687-96. doi: 10.1016/j.thromres.2008.09.015. Epub 2008 Nov 12. Review.</citation>
    <PMID>19007970</PMID>
  </reference>
  <reference>
    <citation>Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011 Dec;93(12):1577-85. doi: 10.1302/0301-620X.93B12.26989. Review.</citation>
    <PMID>22161917</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>piya pinsornsak</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>Peri-articular injection</keyword>
  <keyword>Total knee arthroplasty</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Osteoarthritis, Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

